Please assess the completion status of the following clinical trial:

Trial Title: Hormone Therapy in Treating Patients With Advanced Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * T1c-T2a-b, N1-2 or pN1-2 (after pelvic lymphadenectomy)~ * T2c-T4, N0-2~* Prior external radiotherapy for locally advanced prostatic carcinoma required~* Prior hormone therapy (6 months of combined androgen blockade) for locally advanced prostatic carcinoma required with PSA no greater than 150 ng/mL before administration~* No progressive disease after the 6 months of combined androgen blockage~* No stages T1c/T2a-b with a negative pelvic lymph nodes status that is assessed clinically or surgically~* No lymph node involvement to common iliac and/or periaortic lymph nodes (M1a)~* No external iliac lymph node metastasis more than 5 cm in greatest dimension (N3)~* No distant metastases~PATIENT CHARACTERISTICS:~Age:~* Any age~Performance status:~* WHO 0-2~Life expectancy:~* At least 5 years~Hematopoietic:~* Hemoglobin at least 10 g/dL~* WBC at least 2,000/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No prior or concurrent cancers other than basal cell skin cancer~* No serious nonmalignant disease resulting in a life expectancy of less than 5 years~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior biologic therapy for prostate cancer~Chemotherapy~* No prior chemotherapy for prostate cancer~Endocrine therapy~* See Disease Characteristics~Radiotherapy~* See Disease Characteristics~Surgery~* See Disease Characteristics

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).